国: イスラエル
言語: 英語
ソース: Ministry of Health
OXALIPLATIN
TZAMAL BIO-PHARMA LTD
L01XA03
POWDER FOR SOLUTION FOR INFUSION
OXALIPLATIN 50 MG/VIAL
I.V
Required
MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH, GERMANY
OXALIPLATIN
OXALIPLATIN
Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke‘s C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014).
2022-10-31
וי ל י 2019 ה/דבכנ ת/חקור ,ה/אפור , :ןודנה mg 50 medac Oxaliplatin - ןיטלפילסקוא קאדמ 50 ג"מ 00 mg 1 medac Oxaliplatin - ןיטלפילסקוא קאדמ 00 1 ג"מ mg 0 5 1 medac Oxaliplatin - ןיטלפילסקוא קאדמ 0 15 ג"מ ליעפ ביכרמ : Oxaliplatin medac 50 mg: 50 mg Oxaliplatin Oxaliplatin medac 100 mg: 100 mg Oxaliplatin Oxaliplatin medac 150 mg: 150 mg Oxaliplatin ןונימ תרוצ : Powder For Solution For Infusion תויוותה תורשואמ : Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: •Adjuvant treatment of stage III (Duke‘s C) colon cancer after complete resection of primary tumor. •Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the firstline treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014). תרבח מצ ויב ל - המראפ מ"עב תשקבמ עידוהל םכ לע ה םינוכדע םיאבה ןולעב אפורל ה לש רישכת . רוקמה רישכת ןולע לש ונושלכ ץומיא תובקעב Eloxatin ןפוא ןונימה ףיעסו תויוותהה ףיעס ןכדוע ןתמה ו רישכתה לש ופסונ .תורמחה תועצמאב תנמוסמ הרמחהה תחת וק י ש , ועמשמ תפסות איה ות הל רושקה עדימ הרמח . 4.1 Therapeutic indications Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke‘s C) colon cancer after complete resection of primary tumour • Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014). 4.2 Posology and method of administration Posology FOR ADULTS ONLY The recommended dose for oxa 完全なドキュメントを読む
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT OXALIPLATIN MEDAC 50 MG OXALIPLATIN MEDAC 100 MG 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ One vial with powder for solution for infusion contains 50 mg or 100 mg oxaliplatin. One ml of reconstituted concentrate solution contains 5 mg oxaliplatin. 50 mg vial: Each vial contains 50 mg oxaliplatin for reconstitution in 10 ml of solvent. 100 mg vial: Each vial contains 100 mg oxaliplatin for reconstitution in 20 ml of solvent. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for infusion White to off-white powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke‘s C) colon cancer after complete resection of primary tumour • Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014). 4.2 Posology and method of administration Posology FOR ADULTS ONLY The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m 2 intravenously, repeated every two weeks for 12 cycles (6 months). The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m 2 intravenously, repeated every 2 weeks until disease progression or unacceptable toxicity. 2 The recommended dose of oxaliplatin for the treatment of metastatic pancreatic adenocarcinoma is 85 mg/m 2 given as a 2-hour intravenous infusion, immediately followed by leucovorin (400 mg/m 2 , 2-hour intravenous infusion) with the addition after 30 minutes of irinotecan (180 mg/m 2 , 90-minute intravenous infusion through a Y-connector) and immediately followed by 5-fluorouracil (400 mg/m 2 intravenous bolus followed by 2,400 mg/m 2 continuous intravenous infusion for 46 hours), in 2-week cycles up to 完全なドキュメントを読む